Ádám Andor Kelemen has successfully defended his PhD thesis (Fragment-based approaches in GPCR-targeted drug discovery) at the Budapest University of Technology and Economics. Congratulations!
Junior Prima prize for Péter Ábrányi-Balogh
Péter Ábrányi-Balogh, research fellow of our group, has been awarded the Junior Prima prize in the category of science. Since 2007, the prize is awarded by the Hungarian Development Bank to Hungarian scientists under 33, who have shown exceptional performance and international recognition in scientific research, after a strict protocol for nomination, and assessment by an expert jury.
Featured article on the website of NKFIH
Our recent results in the development of new STAT inhibitors - together with the Moriggl and Gunning groups - were featured on the website of the National Research, Development and Innovation Office of Hungary. The article is also available in Hungarian, featuring a video interview.
Publication prize for László Petri
László Petri, junior researcher of our group and PhD student of the Budapest University of Technology and Economics (BME) has won first prize on the documentary/scientific-educational publication contest organized by BME, the Pro Progressio Foundation and the Hungarian documentary/scientific journal Élet és Tudomány (Life and Science). His work, titled Régi-új fegyver: Kovalens kötés a rák ellen (Old-new weapon: Covalent bond against cancer) will appear in print in Élet és Tudomány, while László will give a radio interview on the Hungarian national (Kossuth) Radio's scientific programme Tér-Idő (Space-Time).
The story of our joint success with the Moriggl and Gunning groups has received wide coverage in mainstream Hungarian media. More details on 24.hu, origo.hu, 444.hu, and rtlklub.hu.
Breakthrough in the therapeutic options for acute myeloid leukemia
As a result of our collaboration with the research groups or Richard Moriggl (Ludwig Boltzmann Institute for Cancer Research and University of Veterinary Medicine, Vienna, Austria) and Patrick Gunning (University of Toronto, Canada), we have recently published a research paper in the Nature-group journal Leukemia, describing a new, promising lead compound for the inhibition of the STAT5 protein. More details are available in Hungarian on the website of the National Research, Development and Innovation Office of Hungary.
Brain Research Days
Our group was represented by Ádám Kelemen, Dóra Judit Kiss, Levente Mihalovits and Zoltán Orgován on the Brain Research Days, an educational/scientific-disseminatory forum organized on March 12-13 at the Eötvös Loránd University of Budapest.
We are happy to welcome David Hamilton from the Vrije Universiteit Amsterdam, who will work on the synthesis and testing of fragment-sized covalent inhibitors.
Best presentation by a young scientist award
Dávid Bajusz was awarded at the 11th Winter Symposium on Chemometrics (held between February 26 - March 02 in St Petersburg, Russia) for the best presentation given by a young researcher, while his coauthor, Anita Rácz has received a Best poster prize. As their reward, the two young researchers will participate in the Copenhagen School of Chemometrics 2018.
It is our pleasure to welcome András Németh, who will work on synthetic preparative chemistry.
We are happy to welcome Gáspár Pándy, who will work on the computational modeling of G-protein coupled receptors.
Tamás Németh has successfully defended his PhD thesis (Synthesis and molecular recognition studies of acridono- and acridino-crown ether-based sensor and selector molecules) at the Budapest University of Technology and Economics. Congratulations!
Helga Bereczki has successfully defended her PhD thesis (Synthesis of functionalized silica aerogels and evaluation of their application fields) at the University of Debrecen. Congratulations!
Dávid Bajusz has successfully defended his PhD thesis (Discovery of novel Janus kinase inhibitors by virtual screening) at the Budapest University of Technology and Economics. Congratulations!
It is our pleasure to welcome Tamás Németh, who will work on synthetic preparative chemistry.
We are happy to welcome the researchers of the University of Ljubljana, Janez Ilaš and Žiga Skok for our joint works on drug design and biochemistry.
New process chemistry grant received
Ministry for National Economy announced that the project entitled „Green chemistry processes for the intermediers of new, innovative agrochemicals at KISCHEMICALS” (GINOP-2.2.1-15/55) has been granted for the consortium of our group and KISCHEMICALS Ltd (KCH). KCH is involved in the production and trading of agrochemical intermediates and active ingredients. Based on our process chemistry expertise we join KCH to widen its product portfolio. The grant allows us to open a new lab at the Pannon University, Veszprém.
API process development with EGIS
National Office of Research, Development and Innovation announced that the project entitled „Research and development of innovative, value added APIs and formulated products for cardiovascular, oncological and CNS diseases” (KFI_16-1-2017-0170) has been granted for EGIS Pharmaceuticals, a member of Servier. Based on the long term partnership with EGIS our group is involved in the process chemistry activity of the project.
It is our pleasure to welcome Moira Rachman from the University of Barcelona for three months. Moira will work on the fragment-based design of novel JAK inhibitors.
Developing new chemistries for pharma research with Mcule
European Commission announced that the project entitled ”Building the Ultimate chemical database for drug discovery” of Mcule, a Hungary based company operating the world’s largest chemical web-shop. Under the H2020 SME Instruments Phase 2 grant (H2020-SMEINST-2-2016-2017) our group receives financial support from Mcule to develop new chemistries for pharma research. This collaboration opens the opportunity to commercialize our scaffolds and libraries to Mcule customers.
We are happy to welcome our newest group member, Helga Bereczki, who will work on synthetic and analytical chemistry.
Grant for a new LC-MS/MS instrument received
Ministry for National Economy announced that our group, in consortium with three further RCNS labs won the research infrastructure grant (VEKOP-2.3.3-15-2016-00011) that allows us to install a new LC-MS/MS at our lab.
We are happy to welcome back Krzysztof Rataj from the Polish Academy of Sciences (Warsaw, Poland), who will collaborate with us in GPCR-directed computational drug discovery.
National Competitiveness and Excellence Program (NVKP) finances a new oncology program in our group
Joining our expertise with FOTOTRONIC Ltd, a member of the Rasopathy consortium (NVKP_16-1-2016-0020) we started a new oncology program aiming the development of KRAS inhibitors. The collaboration is based on the rapidly developing covalent drug discovery platform of our group.
National Competitiveness and Excellence Program (NVKP) Grant
Our group has received a National Competitiveness and Excellence Program (NVKP) Grant from the National Research, Development and Innovation Office to support our proposal on the research of pediatric malignancies, which are the leading causes of death for children below 14 years (NVKP_16-1-2016-0037). Although current haemato-oncological treatments can facilitate full recovery, solid tumours are lethal within 10 years for around half of the affected patients. Through a joint research effort with the 2nd Department of Pediatrics of the Semmelweis University and Meditop Pharmaceutical Ltd., we are planning to utilize state-of-the-art DNA sequencing techniques to identify biomarkers that correlate with the occurrence of these malignancies, propose protein targets for their treatment, and ultimately, identify and synthesize drug candidates that display promising effect on the given target. During this project, we will gain novel insight into the molecular and epidemiological background of the development of solid tumors, create a DNA sequencing test for prevention and targeted diagnostics, and hopefully improve the clinical prospects of pediatric patients with solid tumors.
György M Keserű, head of the research group, has been named as a Fellow of the Royal Society of Chemistry (RSC), a professional society based in the United Kingdom with over 50,000 members worldwide. Founded in 1841, RSC is the largest organization in Europe for advancing the chemical sciences. RSC partners with industry and academia, advises governments on policy, and promotes the talent, collaboration, innovation, information and ideas that lead to great advances in science. The designation Fellow of the Royal Society of Chemistry (FRSC) is given to elected Fellows who have made significant contributions to the chemical sciences. The names of newly elected Fellows are published each year in The Times (London). For more information on the Royal Society of Chemistry, please visit the official website here.
We are happy to welcome back Krzysztof Rataj from the Polish Academy of Sciences (Warsaw, Poland), who will collaborate with us in GPCR-directed drug discovery.
New PhD students join our group
With the support of the FRAGments training NETwork (H2020-MSCA-ITN-2015 No. 675899 FRAGNET), two PhD students have joined our research group for a 3-year period, including a full PhD programme at the Budapest University of Technology and Economics. We are happy to welcome Aaron Keeley (from University College Dublin, Ireland) and Andrea Scarpino (from University of Pisa, Italy), who will conduct synthetic and computational chemical research on fragment-based approaches in the development of covalent binders against relevant drug targets.
We are happy to welcome Janez Ilaš from the University of Ljubljana (Slovenia), who joins our research group for three months to collaborate with us in the biophysical characterization of enzyme inhibitors.
We are happy to welcome three new students: Zsófia Laskai, Márton Nagyházi and Valentina Varga as the newest members as the newest members of the Medicinal Chemistry Research Group.
We are happy to welcome Krzysztof Rataj from the Polish Academy of Sciences (Warsaw, Poland), who joins our research group for two weeks to collaborate with us in GPCR-directed drug discovery.
We are happy to welcome a PhD student, László Petri and five university students, Levente Kollár, Blanka Rinyu, Dénes Sóvári, Gabriella Suhó and Csaba Szabó as the newest members of the Medicinal Chemistry Research Group.
Our paper titled Discovery of Subtype Selective Janus Kinase (JAK) Inhibitors by Structure-Based Virtual Screening is selected for the cover image of the current issue of the Journal of Chemical Information and Modeling.
József Balog has successfully defended his PhD thesis (Synthesis of novel isoquinoline derivatives) at the Budapest University of Technology and Economics. Congratulations, Józsi!
We are happy to welcome Attila Egyed, Dóra Judit Kiss and Zoltán Orgován as the newest members of our research group.
The European Union has granted 3.9 M euro to our consortium from academia and SMEs from Hungary, The Netherlands, Spain, Sweden, Switzerland, and UK. The funding enables the consortium to establish the Marie Curie Innovative Training Network (ITN) FRAGNET of 15 PhD students and explore new research methods and applications in the emerging field of Fragment-Based Lead Discovery.
Hungarian Scientific Research Fund Grant
We are proud to be the recipients of a Hungarian Scientific Research Fund (OTKA) grant for our research on Janus kinase inhibitors. Read more on our ongoing research projects here.